AbbVie (ABBV) Shares Outstanding (2012 - 2026)
AbbVie (ABBV) posted quarterly Shares Outstanding (Entity) of $1.8 billion for Q1 2026, little changed year-over-year from $1.8 billion in Q1 2025, and little changed quarter-over-quarter from $1.8 billion in Q4 2025.
AbbVie (ABBV) Shares Outstanding (2012 - 2026) Analysis & Trends
AbbVie (ABBV) has reported Shares Outstanding (Entity) for 15 consecutive years, with $1.8 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) changed 0.06% year-over-year to $1.8 billion; the TTM figure through Mar 2026 stood at $1.8 billion (changed 0.06% YoY), while the FY2025 annual figure was $1.8 billion, changed 0.17% from the prior year.
- Shares Outstanding (Entity) steadied at $1.8 billion in Q1 2026 per ABBV's latest filing, from $1.8 billion in the prior quarter.
- Across five years, Shares Outstanding (Entity) topped out at $1.8 billion in Q4 2022 and bottomed at $1.8 billion in Q1 2023.
- Historically, Shares Outstanding (Entity) has averaged $1.8 billion across 5 years, with a median of $1.8 billion in 2023.
- Annual changes were most pronounced in 2023 — Shares Outstanding (Entity) declined 0.17% — and 2025, when it climbed 0.17%.
- AbbVie's Shares Outstanding (Entity) stood at $1.8 billion in 2022, then declined by 0.17% to $1.8 billion in 2023, then decreased by 0.06% to $1.8 billion in 2024, then gained by 0.17% to $1.8 billion in 2025, then declined by 0.06% to $1.8 billion in 2026.
- Business Quant data shows ABBV's Shares Outstanding (Entity) at $1.8 billion in Q1 2026, $1.8 billion in Q4 2025, and $1.8 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 2.41 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 1.77 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 2.47 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 1.91 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 1.55 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 540.00 Mn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 1.24 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 5.70 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 2.03 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 1.20 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.77 Bn |
| Mar 31, 2026 | 1.77 Bn |
| Dec 31, 2025 | 1.77 Bn |
| Sep 30, 2025 | 1.77 Bn |
| Jun 30, 2025 | 1.77 Bn |
| Mar 31, 2025 | 1.77 Bn |
| Dec 31, 2024 | 1.77 Bn |
| Sep 30, 2024 | 1.77 Bn |
| Jun 30, 2024 | 1.77 Bn |
| Mar 31, 2024 | 1.77 Bn |
| Dec 31, 2023 | 1.77 Bn |
| Sep 30, 2023 | 1.77 Bn |
| Jun 30, 2023 | 1.77 Bn |
| Mar 31, 2023 | 1.77 Bn |
| Dec 31, 2022 | 1.77 Bn |
| Sep 30, 2022 | 1.77 Bn |
| Jun 30, 2022 | 1.77 Bn |
| Mar 31, 2022 | 1.77 Bn |
| Dec 31, 2021 | 1.77 Bn |
| Sep 30, 2021 | 1.77 Bn |